CRBUNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Caribou Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.46−0.01 (-1.26%)
Close on Oct 19, 2026
- Market cap
- $46.86M
- P/E (TTM)
- –
- Dividend yield
- –
Caribou Biosciences, Inc. revenue by segment
By business segment
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.49M | $2.26M | $3.77M | $1.82M | $1.66M | $2.22M | $1.90M | $1.66M | $3.44M | $2.27M | $2.35M | $23.29M | 99.5% | -10.2% |
| Rest of world | $7.00K | $140.00K | $170.00K | $377.00K | $1.01M | $129.00K | $177.00K | $367.00K | $20.00K | $160.00K | $1.20M | $377.00K | 0.5% | -99.3% |
From the segment and revenue-disaggregation notes of Caribou Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.